Organization (Hospital)
Shaare Zedek Medical Center
ClinicalTrials.gov lists Shaare Zedek Medical Center as lead sponsor of 193 trials. It has 16 active development programs and 42 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Shaare Zedek Medical Center: 193 lead-sponsored trials and 1 legal-entity registration.
Disease areas (173)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Inflammatory Bowel Diseases | 14 |
| Pain | 13 |
| Crohn Disease | 9 |
| Infertility | 9 |
| Ductus Arteriosus, Patent | 8 |
Showing 5 of 173 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 7 |
| 2021 | 6 |
| 2020 | 11 |
| 2019 | 4 |
| 2018 | 6 |
| 2017 | 11 |
Showing 10 of 24 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; 5 of 6 predicted trials reach the 36-month horizon; registered median of 18 months across 67 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Vyxeos | Leukemia, Myeloid, Acute | Phase 2 | 1 |
| Gemtuzumab Ozogamicin | Leukemia, Myeloid, Acute | Phase 2 | 1 |
| Naxitamab | Neuroblastoma | Phase 2 | 1 |
| Ambroxol | Gaucher Disease | Phase 2 | 1 |
| Chemotherapy Drugs, Cancer | Breast Neoplasms | Phase 1/2 | 1 |
Showing 5 of 16 active programs.
Approved assets (42)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| METHYLPHENIDATE | 3 |
| Velaglucerase Alfa | 2 |
| Varenicline | 2 |
| Physiotherapy | 1 |
| Enoxaparine | 1 |
Showing 5 of 42 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 45% hit target (n=22) | 35% on time (n=20) |
Journals published in (165)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Fertility and sterility | 16 |
| Human reproduction (Oxford, England) | 12 |
| Reproductive biomedicine online | 12 |
| The Cochrane database of systematic reviews | 7 |
| Chest | 6 |
Showing 5 of 165 journals.
Organization relationships (35)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Soroka University Medical Center | Co sponsors trial with | 4 |
| Hadassah Medical Organization | Co sponsors trial with | 3 |
| Sydney Children’s Hospitals Network | Co sponsors trial with | 2 |
| Tel Aviv Sourasky Medical Center | Co sponsors trial with | 2 |
| Rebecca Sieff Hospital | Co sponsors trial with | 2 |
Showing 5 of 35 relationships.
Latest dated events (210)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 210 events.
Biomarker capability evidence (83)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGA | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 83 evidence rows.
Biomarkers this organization publishes on (393)
Shown in this order: most publications first.
Showing 5 of 393 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.